secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2026-07-01T20:09:09+00:00
Accession:  0001294133-26-000025
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen appoints Andy Reding as COO effective July 6, 2026
---------------------------------------------------------

- Andy Reding appointed to newly created COO role, effective July 6, 2026.
- Reding previously Chief Commercial Officer at Viant Medical and VP/GM at Hillrom Respiratory Health.
- Compensation: $500k base salary, 70% target bonus, $100k sign-on bonus, 130,000 RSUs vesting over 3 years.
- Severance: 12 months base salary if terminated without cause outside change of control; 24 months within change of control period.
- Inducement equity award granted under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000129413326000025/0001294133-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000129413326000025/ingn-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001294133-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer